Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

EHA 2018

14 - 17 Jun 2018
Stockholmsmässan, Stockholm, Sweden
Videos
News
IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development...
Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna...
IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development... ( Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria )
10 Jul 2018
CDK6 a transcriptional regulator in AML
Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna...
CDK6 a transcriptional regulator in AML ( Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria )
27 Jun 2018
Treating CLL with obinutuzumab
Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany
Treating CLL with obinutuzumab ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )
17 Jun 2018
Protein expression in CD138 plasma cells predicts prognosis in MM patients
Dr Irena Misiewicz-Krzeminska - Cancer Research Center, Salamanca, Spain
Protein expression in CD138 plasma cells predicts prognosis in MM patients ( Dr Irena Misiewicz-Krzeminska - Cancer Research Center, Salamanca, Spain )
17 Jun 2018
Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations
Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy
Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations ( Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy )
17 Jun 2018
First in-human trial of AMV564 for AML
Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA
First in-human trial of AMV564 for AML ( Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA )
17 Jun 2018
SETBP1 induces transcription of developmental genes
Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy
SETBP1 induces transcription of developmental genes ( Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy )
17 Jun 2018
Combination therapy for CLL in the CAPTIVATE trial
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
Combination therapy for CLL in the CAPTIVATE trial ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
17 Jun 2018
Efficacy of novel agents in r/r T pro-lymphocytic leukaemia
Prof Philipp Staber - Medical University of Vienna, Vienna, Austria
Efficacy of novel agents in r/r T pro-lymphocytic leukaemia ( Prof Philipp Staber - Medical University of Vienna, Vienna, Austria )
17 Jun 2018
Isatuximab in combination to treat relapsed/refractory MM
Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma...
Isatuximab in combination to treat relapsed/refractory MM ( Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation )
17 Jun 2018
Venetoclax in patients with previously treated WM
Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA
Venetoclax in patients with previously treated WM ( Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA )
17 Jun 2018
Single cell profiling reveals key differences in architecture of stem and...
Dr Anindita Roy - University of Oxford, Oxford, UK
Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life ( Dr Anindita Roy - University of Oxford, Oxford, UK )
17 Jun 2018
ICLL07 FILO study: Minimal residual disease still detectable after first line...
Prof Pierre Feugier - University of Lorraine, Nancy, France
ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy ( Prof Pierre Feugier - University of Lorraine, Nancy, France )
17 Jun 2018
Even late progressors with high risk factors in PRIMA prognostic index are more...
Prof Marek Trněný - Charles University, Prague, Czech Republic
Even late progressors with high risk factors in PRIMA prognostic index are more likely to die ( Prof Marek Trněný - Charles University, Prague, Czech Republic )
17 Jun 2018
Patient relevant outcomes and advocacy
Jan Geissler - CML Advocates Network, EuroBloodNET ePAG
Patient relevant outcomes and advocacy ( Jan Geissler - CML Advocates Network, EuroBloodNET ePAG )
17 Jun 2018
The mutational landscape of AML
Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany
The mutational landscape of AML ( Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany )
17 Jun 2018
Development of a risk stratifying prognostic index for ALL
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Development of a risk stratifying prognostic index for ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
17 Jun 2018
Specification of haematopoetic stem cell fate via modulation of mitochondrial...
Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland
Specification of haematopoetic stem cell fate via modulation of mitochondrial activity ( Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland )
17 Jun 2018
Onset and treatment of infantile leukaemia
Dr Anindita Roy - University of Oxford, Oxford, UK
Onset and treatment of infantile leukaemia ( Dr Anindita Roy - University of Oxford, Oxford, UK )
17 Jun 2018
Novel CD22 CAR-T therapy for paediatric leukaemia
Dr Jing Pan - Beijing Boren Hospital, Beijing, China
Novel CD22 CAR-T therapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )
16 Jun 2018
Lymphoma guidelines in Venezuela
Dr Maria Alejandra Torres Viera - Clínica Santa Sofía, Caracas, Venezuela
Lymphoma guidelines in Venezuela ( Dr Maria Alejandra Torres Viera - Clínica Santa Sofía, Caracas, Venezuela )
16 Jun 2018
Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma
Dr Ramon Garcia Sanz - Hospital Universitario de Salamanca, Salamanca, Spain
Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma ( Dr Ramon Garcia Sanz - Hospital Universitario de Salamanca, Salamanca, Spain )
16 Jun 2018
EHA 2018: Research, collaboration and working towards cures
Prof Pieter Sonneveld - Erasmus MC, Rotterdam, Holland
EHA 2018: Research, collaboration and working towards cures ( Prof Pieter Sonneveld - Erasmus MC, Rotterdam, Holland )
16 Jun 2018
Educational focus on immunotherapy at EHA
Prof John Gribben - Barts Cancer Institute, London, United Kingdom
Educational focus on immunotherapy at EHA ( Prof John Gribben - Barts Cancer Institute, London, United Kingdom )
16 Jun 2018
ADC polatuzumab vedotin in combinations for relapsed lymphoma
Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada
ADC polatuzumab vedotin in combinations for relapsed lymphoma ( Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada )
16 Jun 2018
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia
Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School...
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece )
16 Jun 2018
EHA 2018: Initial results of the INSIGHT trial in multiple myeloma
Prof Efstathios Kastritis and Dr Zhengzheng Fu
EHA 2018: Initial results of the INSIGHT trial in multiple myeloma ( Prof Efstathios Kastritis and Dr Zhengzheng Fu )
16 Jun 2018
A new anti-CD22 CAR T immunotherapy for paediatric leukaemia
Dr Jing Pan - Beijing Boren Hospital, Beijing, China
A new anti-CD22 CAR T immunotherapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )
16 Jun 2018
EHA Topics in focus : Immunotherapy
Prof John Gribben - Barts Cancer Institute, London, United Kingdom
EHA Topics in focus : Immunotherapy ( Prof John Gribben - Barts Cancer Institute, London, United Kingdom )
16 Jun 2018
Novel ADC for relapsed/refractory lymphoma
Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada
Novel ADC for relapsed/refractory lymphoma ( Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada )
16 Jun 2018
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia
Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School...
iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece )
16 Jun 2018
EHA 2018: The unmet needs in maintenance therapy for multiple myeloma
Prof Meletios Dimopoulos, Dr Shaji Kumar, Prof Meral Beksaç and Prof Wee Joo...
EHA 2018: The unmet needs in maintenance therapy for multiple myeloma ( Prof Meletios Dimopoulos, Dr Shaji Kumar, Prof Meral Beksaç and Prof Wee Joo Chng )
15 Jun 2018
EHA 2018: Results of the OPTIMISMM trial
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
EHA 2018: Results of the OPTIMISMM trial ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
15 Jun 2018
Updated results from a phase I trial of CAR-T cell therapy for r/rMM
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
Updated results from a phase I trial of CAR-T cell therapy for r/rMM ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
15 Jun 2018
Fatigue at baseline predicts shorter survival in older patients with a...
Prof Reinhard Stauder - University of Innsbruck, Innsbruck, Austria
Fatigue at baseline predicts shorter survival in older patients with a haematological malignancy ( Prof Reinhard Stauder - University of Innsbruck, Innsbruck, Austria )
15 Jun 2018
Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma
Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina
Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma ( Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina )
15 Jun 2018
Updates from Myeloma XI trial
Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK
Updates from Myeloma XI trial ( Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK )
15 Jun 2018
Ribosomal lesions promote oncogenic mutagenesis
Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium
Ribosomal lesions promote oncogenic mutagenesis ( Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium )
15 Jun 2018
Updated data from the FORTE trial of carfilzomib plus lenalidomide or...
Dr Francesca Gay - University of Torino, Torino, Italy
Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )
15 Jun 2018
Interim results of RELEVANCE trial in follicular lymphoma
Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France
Interim results of RELEVANCE trial in follicular lymphoma ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )
15 Jun 2018
Disease control in advanced Hodgkin lymphoma
Dr Olivier Casasnovas - CHU de Dijon, Dijon, France
Disease control in advanced Hodgkin lymphoma ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )
15 Jun 2018
Improved OS with obinutuzumab in the CLL11 study
Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany
Improved OS with obinutuzumab in the CLL11 study ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )
15 Jun 2018
Rituximab in combination therapies for FL: Interim results
Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France
Rituximab in combination therapies for FL: Interim results ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )
15 Jun 2018
Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results
Dr Olivier Casasnovas - CHU de Dijon, Dijon, France
Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )
15 Jun 2018
Mapping 3D genome dynamics in B cells
Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain
Mapping 3D genome dynamics in B cells ( Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain )
15 Jun 2018
Update on bb2121 for relapsed myeloma
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
Update on bb2121 for relapsed myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
15 Jun 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation